approval
saveLIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
community read0 votes
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INTRAVENOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 1 completionOncoNano Medicine Inc — cemiplimab (Phase I Trial Completion)Apr 30, 2026 · 154d ago
- phase 2 completionRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)Apr 30, 2026 · 154d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalOct 29, 2025 · 337d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalOct 8, 2025 · 358d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 5, 2024 · 909d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalMar 6, 2024 · 939d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 28, 2023 · 1252d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 28, 2023 · 1252d ago
same company · ±60 days · 5
- approvalcemiplimab: LIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalFeb 9, 2021
- approvalevinacumab: EVKEEZA (EVINACUMAB-DGNB) — FDA approvalFeb 11, 2021
- approvalcemiplimab: LIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalFeb 22, 2021
- approvalalirocumab: PRALUENT (ALIROCUMAB) — FDA approvalApr 1, 2021
- approvalalirocumab: PRALUENT (ALIROCUMAB) — FDA approvalApr 1, 2021
🐶 often sniffed alongside
top 8- tagApproval60 co-mentions · 15 sources
- drugLIBTAYO60 co-mentions · 15 sources
- tagOncology12 co-mentions · 3 sources
- tagPulmonology4 co-mentions · 1 sources
- tagNSCLC3 co-mentions · 1 sources
- tagBreast Cancer3 co-mentions · 1 sources
- tagMelanoma3 co-mentions · 1 sources
- tagColorectal Cancer2 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that